Member Info for Zendog

Looking forward to excitement won 30th but wondering, how much of it will be of actual achievement (such as sales of covid test) and how much of the anticipated coming soo variety?

Hopefully the SP low has passed, Friday's rise can be sustained and, the new experienced Director will bring about 'delivery' improvement. However, solid Covid test sales news is still the key to SP in the short term, as real cancer treatment news is of a one -two year timescale. (Even though the CEO will undoubtedly already be very excited in regular VOX etc interviews in anticipation!)

BBtablets marketing points seem to sum up Avacta's actual situation well - the excited (over-optimistic /unrealistic?) CEO 'ramped' the Covid test as a product out of all proportion to its real world existence and contracted production capacity. Inexperience in negotiating regulatory / political hurdles, product development and marketing became obvious, especially relative to sales progress made by others and despite, apparently, having the best test. One year on from the original CEO-raised expectation of product sales in summer 2020, deals with manufacturers and distributors remain very disappointing in practice in respect of actual production and sales. (Even now only a few boxes sold to Avacta fans? If it was better, surley they'd have told about it?). Inevitably ending in loss of trust /faith and SP decline from what are now obviously 'spikes'.

Many 'investors '- like me - made money on original holdings but, are now frustrated sitting on current losses and 'what might have been', having got drawn into rebuying / buying more at too-high prices. I have to keep reminding myself - I originally bought to be in 'early' on the cancer treatment hopes. In that context , early Covid based gains and, any that may still come, were /are therefore a bonus.
I'm holding because , if the cancer treatment succeeds, it could be massive.

....and shareholders and non shareholders should able to comment on this bulletin board, whether comments are positive or negative. Surely you dont just want excitement about prospects and nothing else on here? It's valid to point out risks and performance issues. In fact such Posts are good reality checks and, here's one:-
In making his first "excited" announcements about the Covid test in 2020, CEO Smith lead people to believe there would be an LFT test mass selling in summer 2020. It's now summer 2021 and still no sales at all. That suggests there are some organisational and performance or prioritisation issues to address within Avacta. It can not all be 'matters outside their control'.

By the way, I'm a shareholder.

So some good news in the week with formal EU recognition of the Covid test. But still no sales and no apparent sales strategy except posting of availability on websites. This SP will slide until firm, material (to SP) sales are achieved. Will this be in July? August? This calendar year? My investment in this company is now very much one of loss and hope ,not belief. I really dont want to hear any more "excitement" of the CEO. I want to hear of sales.

Templar, lets hope you're right nd it more than coincident remarks by the Avacta CEO. It also begs the question, what has Avacta been doing with Medusa since last years announcement? There's no doubt the SP is in need of Avacta actually selling some tests.

If this is the Avacta test, haven't BioServeUK described the testing procedure wrongly? They've set out a mouth/throat based sample procedure? doesn't the Avacta test require a nasal sample?

...except that Innova sales somewhat exceed Avactas!
When will Avacta start catching up? Have they got a Marketing Team? (I know they have but, it doesn't seem like it).

Scardey_cat,
Thanks for your excellent letter to Ms Bradshaw. I recommend you send it to MPs Steve Baker and Mark Harper as they may actually take it up with the Government and DHSC . Will you do that or, could I copy it to them?
Zendog

I think they might get in on sale in 2 022.

..and Avacta dependent on Indian Variant test samples from PHE.... dont' hold your breath while waiting!

After 2020 'Covid test sales' became 2021 , Avacta is now "poised" (emphasised the CEO in presentation today ) to commence some LFT sales and ramp up over "coming months". It will be 2022 before any serious sales? I hope the LFT is not a perpetual 'jackanory' but, it has drifted very badly.
However, I'm holding because of the Precision cancer therapy - despite that being another 'hope' requiring 'shoot the moon' faith and acceptance of risk.
..based on the Covid LFT experience, we can but hope and dream. that that Therapeutics Team are better project managers. But if it works...it could be very, very BIG

If the EU wants to shoot itself in the foot again! (Though scope is limited. Both feet already well and truly shattered).
Perhaps buying the best available test is their chance for redemption.
Just hope Avacta dont let themselves get bullied into a low price.
And, there's a world to still play for outside the EU.

It seems Avacta had no marketing strategy ready to go with the CE confirmation, just an update of its website?
Sadly, does seem to be something of a commercialisation shambles?

Good news from the MHRA .....and showing they can register device within a few days of a valid submission after all.
I wonder how close Avacta is to any orders. in the June 1st RNS the CEO said:-

"....the Company has continued its discussions with distributors and customers for the AffiDX® antigen test and does not anticipate that the [MHRA submission] error will cause a delay to first commercial sales of the product".

I read that as fact that, between May 10th and now, they were not anywhere near Orders. And, possibly they're not imminent even now. But. maybe it meant that they knew there was a particular timeline (perhaps within Government procurement) that meant the May 10th to now period was not on the critical path?

..and let's hope that critical path to orders is now , with Orders soon....
Please, not another false dawn.

..registered in 2019?

Another year ...makes it 2022 . I've had a suspicion for awhile that the CEO gets his years mixed up. It explains quite a lot of mi-understanding people on this BB have had with what he has forecast.

Larsh - I think it is probably very simple why this happened: Avacta/Mologic did not follow up on the supposed submission by their contractor on May 10th with a basic check that it had been done correctly and left it too long before looking into it - hence 18 days lost. It's not rocket science -just implementation of basic commercial risk mitigation procedures.

What happened is , it took 18 days for Avacta / Mologic (the company / Partner company) to check and resolve that a contractor carrying out critical business on behalf of the company / Partner undertook that business right. And, in the context that the Avacta CEO stated that the submission had been made on may 10th and explicit commercial sales promotion would following within "coming days" (of May 10th).

The RNS incudes :-
"In the meantime, the Company has continued its discussions with distributors and customers for the AffiDX® antigen test and does not anticipate that the error will cause a delay to first commercial sales of the product". This can surely only mean , there are no specific sales yet lined up? If there were sales lined up, the delay from 10th to now and the next few days would already have been a £ loss. Evidence mounting this is a shambles?

whether Mologic is third party or second party or even first party (if they are a "Partner"), ..still niave trust in the contractor appointed to make the submission. (Who appointed the contractor, Mologic or Mologic and AVacta jointly ? ).